Neurofibromatosis type 2;Neurofibromatosis tipo 2

Acta Otorrinolaringologica Espanola

Volumn 61, Issue 4, 2010, Pages 306-311

  Pérez Grau, Marta ^a   Miró, Núria ^a   Prades, José ^a   Vergés, Juan ^a   Lareo, Susana ^a   Roca Ribas, Francesc ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Brain stem implant; Meningioma; NF2; Vestibular schwannoma

Indexed keywords

AUTOSOMAL DOMINANT DISORDER; BRAIN STEM; CANCER SURGERY; CATARACT; CENTRAL NERVOUS SYSTEM TUMOR; COCHLEAR NERVE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FAMILY HISTORY; GENE; GENE MUTATION; GLIOMA; HEARING; HUMAN; INCIDENCE; INTRACRANIAL TUMOR; MENINGIOMA; MORBIDITY; MORTALITY; MOSAICISM; NERVE SURGERY; NEURILEMOMA; NEUROFIBROMATOSIS; NF2 GENE; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; SHORT SURVEY; TUMOR GROWTH; VESTIBULAR NERVE;

HUMANS; NEUROFIBROMATOSIS 2;

EID: 77954621473     PISSN: 00016519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otorri.2009.12.005     Document Type: Short Survey

References (22)

1. Seizinger B.R., Rouleau G.A., Ozelius L.G., Lane A.H., Faryniarz A.G., Chao M.V., et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve grouth factor receptor gene. Cell 1987, 49:589-594.
2. Rouleau G., Seizinger B.R., Wertelecki W., Haines J.L., Superneau D.W., Martuza R.L., et al. Genetic linkageanalysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987, 329:246-248.
3. Evans D.G., Moran A., King A., Saeed S., Gurusinghe N., Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005, 26:93-97.
4. Gutmann D.H., Sherman L., Seftor L., Haipek C., Lu K.H., Hendrix M. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum Mol Genet 1999, 8:267-275.
5. Baser M.E., Friedman J.M., Aeschliman D., Joe H., Wallace A.J., Ramsden R.T., et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002, 71:715-723.
6. Evans D.G., Baser M.E., O'Reilly B., Rowe J., Gleeson M., Saeed S., et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005, 19:5-12.
7. Ruggieri M., Iannetti P., Polizzi A., La Mantia I., Spalice A., Giliberto O., et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 2005, 36:21-34.
8. Dow G., Biggs N., Evans G., Gillespie J., Ramsden R., King A. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history?. J Neurosurg Spine 2005, 2:574-579.
9. Perry A., Giannini C., Raghavan R., Scheithauer B.W., Banerjee R., Margraf L., et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001, 60:994-1003.
10. Evans D.G., Birch J.M., Ramsden R.T. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999, 81:496-499.
11. Sperfeld A.D., Hein C., Schroder J.M., Ludolph A.C., Hanemann C.O. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002, 125:996-1004.
12. National Institutes of Health Consensus Development Conference Statement on Neurofibromatosis. Arch Neurol 1987; 45: 575-9.
13. Moyhuddin A., Baser M.E., Watson C., Purcell S., Ramsden R.T., Heiberg A., et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003, 40:459-463.
14. Evans D.G., Ramsden R.T., Gokhale C., Bowers N., Huson S.M., Wallace A. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?. Clin Genet 2007, 71:354-358.
15. Baser M.E., Friedman J.M., Evans D.G. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 2006, 66:730-732.
16. Evans D.G., Ramsden R.T., Shenton A., Gokhale C., Bowers N.L., Huson S.M., et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007, 44:424-428.
17. Kluwe L., Mautner V., Heinrich B., Dezube R., Jacoby L.B., Friedrich R.E., et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003, 40:109-114.
18. Evans D.G., Wallace A.J., Wu C.L., Trueman L., Ramsden R.T., Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998, 63:727-736.
19. Baser M.E., Evans D.G., Jackler R.K., et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 2000, 82:998.
20. Rowe J.G., Radatz M.W., Walton L., Soanes T., Rodgers J., Kemeny A.A. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 2003, 74:1288-1293.
21. Baser M.E., Friedman J.M., Aeschliman D., et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002, 71:715-723.
22. Asthagiri A.R., Parry D.M., Butman J.A., Kim H.J., Tsilou E.T., Zhuang Z., et al. Neurofibromatomatosis type 2. Lancet 2009, 373:1974-1986.